Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) insider Brian Kenneth Roberts acquired 2,500 shares of Rezolute stock in a transaction that occurred on Wednesday, June 25th. The stock was acquired at an average price of $4.38 per share, with a total value of $10,950.00. Following the completion of the acquisition, the insider now directly owns 15,500 shares in the company, valued at $67,890. This represents a 19.23% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Rezolute Stock Performance

Shares of Rezolute stock traded up $0.04 on Friday, hitting $4.35. 10,248,992 shares of the company's stock were exchanged, compared to its average volume of 628,561. Rezolute, Inc. has a 1 year low of $2.22 and a 1 year high of $6.19. The company has a 50-day simple moving average of $3.98 and a 200-day simple moving average of $4.08. The stock has a market capitalization of $372.01 million, a PE ratio of -3.78 and a beta of 1.04.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, analysts expect that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Rezolute

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC boosted its position in shares of Rezolute by 10.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock worth $14,004,000 after purchasing an additional 280,861 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Rezolute by 699.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock worth $12,377,000 after buying an additional 2,210,038 shares during the period. Affinity Asset Advisors LLC increased its stake in Rezolute by 7.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,700,000 shares of the company's stock worth $4,930,000 after buying an additional 125,000 shares in the last quarter. Woodline Partners LP increased its stake in Rezolute by 2,817.1% in the 4th quarter. Woodline Partners LP now owns 1,089,345 shares of the company's stock worth $5,338,000 after buying an additional 1,052,002 shares in the last quarter. Finally, Susquehanna International Group LLP raised its holdings in Rezolute by 749.0% during the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock valued at $4,379,000 after acquiring an additional 788,349 shares during the period. Institutional investors own 82.97% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on RZLT shares. Wedbush restated an "outperform" rating and set a $12.00 price objective on shares of Rezolute in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Rezolute in a research note on Monday, April 28th. Finally, Wall Street Zen downgraded Rezolute from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.83.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.